Avantor (NYSE:AVTR) Price Target Lowered to $26.00 at Stifel Nicolaus

Avantor (NYSE:AVTR) had its target price trimmed by Stifel Nicolaus from $28.00 to $26.00 in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

AVTR has been the topic of a number of other reports. Raymond James dropped their target price on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Wells Fargo & Company reduced their price objective on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. UBS Group restated a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Robert W. Baird cut their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, Barclays lowered their price objective on Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Monday. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Avantor currently has an average rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Trading Down 0.9 %

Shares of AVTR stock opened at $19.00 on Monday. Avantor has a 52-week low of $18.49 and a 52-week high of $28.00. The company has a 50-day simple moving average of $21.73 and a two-hundred day simple moving average of $23.47. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company has a market capitalization of $12.93 billion, a price-to-earnings ratio of 41.30, a PEG ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period in the previous year, the company earned $0.22 EPS. Research analysts anticipate that Avantor will post 0.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of AVTR. MassMutual Private Wealth & Trust FSB raised its position in Avantor by 99.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after purchasing an additional 625 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Avantor by 106.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after purchasing an additional 830 shares during the period. UMB Bank n.a. purchased a new position in shares of Avantor during the third quarter valued at about $49,000. Global Retirement Partners LLC boosted its position in Avantor by 76.7% during the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after acquiring an additional 1,067 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in shares of Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.